Research Type: Extramural
Professor Liu and his team are investigating how particular proteins affect the development and growth of tumours in children with TERT-rearranged neuroblastoma.
This project will develop methods for upscaling CAR T-cell production in NSW – accelerating the introduction of this cutting-edge therapy and making treatment more affordable.
This project aims to show that certain nerve growth factors (proteins that stimulate the growth of nerves) are effective biomarkers for prostate cancer.
This research has revealed a significant increase in rates of anal cancer in high-income countries, including Australia, since the late 1980s.
Associate Professor Holst’s team have been working on a new type of anti-cancer drug that can ‘starve’ prostate cancer cells and stop their growth.
Using the latest approaches to genomic sequencing, Associate Professor Marcel Dinger and his team have identified genes that contribute to rare head and neck cancers.
Resistance to endocrine therapies is common, affecting around 40% of people who undergo treatment for breast cancer. Dr Caldon’s team investigated the underlying causes of this resistance.
Professor De Fazio’s team investigated a rare and treatment-resistant subtype of ovarian cancer. Their approach has a better chance of predicting which treatments will work.
The project has strong potential to achieve major benefits for patient care, because it brings the concept of personalised medicine much closer to reality.
This project is a critical step to expand treatment options and could also pave the way for development of immune therapies for breast cancer.